Oxford Biomedica (LON:OXB) Stock Passes Below 200-Day Moving Average – Here’s What Happened

Shares of Oxford Biomedica plc (LON:OXB) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 580.92 and traded as low as GBX 450.50. Oxford Biomedica shares last traded at GBX 458.50, with a volume of 374,419 shares.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on OXB. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 8.27 target price on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Royal Bank Of Canada restated an “outperform” rating and issued a GBX 900 price objective on shares of Oxford Biomedica in a report on Tuesday, September 1st. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 595 price objective on shares of Oxford Biomedica in a research note on Wednesday, September 2nd. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of GBX 580.85.

Oxford Biomedica Stock Performance

The stock has a 50 day simple moving average of GBX 522.68 and a 200 day simple moving average of GBX 580.07. The company has a market cap of £556.82 million, a price-to-earnings ratio of -17.09 and a beta of 1.09. The company has a quick ratio of 1.67, a current ratio of 2.20 and a debt-to-equity ratio of 162.16.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.